Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.
IPO Year: 2018
Exchange: NASDAQ
Website: adialpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | $8.00 | Buy | Rodman & Renshaw |
| 10/13/2021 | $12.00 | Buy | Brookline Capital |
| 6/29/2021 | $5.00 | Buy | Litchfield Hills |
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)